Back

Single-Domain Antibody-Based Protein Degrader for Synucleinopathies

Jiang, Y.; Lin, Y.; Tetlow, A. M.; Pan, R.; Ji, C.; Kong, X.-P.; Congdon, E. E.; Sigurdsson, E. M.

2024-03-13 neuroscience
10.1101/2024.03.11.584473 bioRxiv
Show abstract

Synucleinopathies are a group of neurodegenerative diseases characterized by the accumulation of -synuclein (-syn) in the brain, leading to motor and neuropsychiatric symptoms. Currently, there are no known cures for synucleinopathies, and treatments mainly focus on symptom management. In this study, we developed a single-domain antibody (sdAb)-based protein degrader with features designed to enhance proteasomal degradation of -syn. This sdAb derivative targets both -syn and Cereblon (CRBN), a substrate-receptor for the E3-ubiquitin ligase CRL4CRBN, and thereby induces -syn ubiquitination and proteasomal degradation. Our results indicate that this therapeutic candidate enhances proteasomal degradation of -syn, in addition to the endogenous lysosomal degradation machinery. By promoting proteasomal degradation of -syn, we improved clearance of -syn in primary culture and mouse models of synucleinopathy. These findings indicate that our sdAb-based protein degrader is a promising therapeutic candidate for synucleinopathies. Considering that only a small percentage of antibodies enter the brain, more potent sdAbs with greater brain entry than whole antibodies could enhance clinical benefits of antibody-based therapies.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
ACS Chemical Neuroscience
● 67 papers in training set
Top 0.1%
9.7%
Similar papers in this journal
2
npj Parkinson's Disease
○ 105 papers in training set
Top 0.3%
7.9%
Similar papers in this journal
3
Molecular Therapy
○ 81 papers in training set
Top 0.2%
7.3%
Similar papers in this journal
4
Journal of Neurochemistry
○ 53 papers in training set
Top 0.1%
4.9%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 28%
4.3%
Similar papers in this journal
6
Brain
◐ 168 papers in training set
Top 0.9%
4.0%
7
Journal of Biological Chemistry
○ 690 papers in training set
Top 3%
3.2%
8
Science Advances
● 1243 papers in training set
Top 10%
3.2%
9
iScience
○ 1154 papers in training set
Top 9%
2.8%
10
Molecular Neurodegeneration
○ 55 papers in training set
Top 0.7%
2.8%
50% of probability mass above
11
Nature Communications
○ 5641 papers in training set
Top 38%
2.6%
12
Scientific Reports
○ 3612 papers in training set
Top 40%
2.4%
13
Cell Reports
○ 1498 papers in training set
Top 15%
2.4%
14
Science Translational Medicine
● 127 papers in training set
Top 1%
2.1%
15
PLOS ONE
● 5266 papers in training set
Top 43%
2.1%
16
Neurobiology of Disease
○ 148 papers in training set
Top 2%
1.9%
17
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.9%
1.7%
18
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.6%
1.3%
19
Alzheimer's & Dementia
177 papers in training set
Top 2%
1.1%
20
JCI Insight
● 277 papers in training set
Top 6%
1.1%
21
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 34%
1.1%
22
Neurotherapeutics
○ 14 papers in training set
Top 0.1%
1.1%
23
Translational Neurodegeneration
○ 10 papers in training set
Top 0.2%
1.1%
24
ACS Central Science
● 71 papers in training set
Top 1%
1.1%
25
Acta Neuropathologica Communications
○ 89 papers in training set
Top 2%
1.1%
26
Cells
○ 249 papers in training set
Top 6%
1.0%
27
International Journal of Molecular Sciences
○ 494 papers in training set
Top 15%
0.8%
28
Advanced Science
○ 286 papers in training set
Top 9%
0.8%
29
Fluids and Barriers of the CNS
○ 28 papers in training set
Top 0.5%
0.8%
30
Communications Biology
○ 993 papers in training set
Top 34%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.